Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Treats moderately to severely active Crohn’s disease. Sold as Yusimry. Every FDA application for this active ingredient. Boxed warningOrphan exclusivity to Feb 24, 2028
As of Nov 22, 2026, FDA lists 1 application for Adalimumab-aqvh (sold as Yusimry), first approved Dec 17, 2021, with 1 new use approved and 0 published complete response letters.
Each condition ChEMBL records for this drug, with the furthest stage reached and the trials it cites; approved means approved for that use somewhere, not necessarily in the US
Stopped early: “Study has been prematurely terminated as the interim analysis 1 efficacy results met the prespecified futility criteria related to the primary endpoint.”
Cases reported to FDA naming this drug as the primary suspect, 2025 Q4 to 2026 Q3, from FDA's quarterly files. A report does not show the drug caused the event.
First approved in Japan 164 months before the US. PMDA's English list since 2008, matched by ingredient; see all Japanese approvals
HumiraDrugs with a new indication and a new dosage for the treatment of non-radiographic axial spondyloarthritis in patients who have not responded sufficiently… · AbbVie GK · Feb 20, 2025
HumiraDrugs with a new indication and a new dosage, including a new additional pediatric dosage, for the treatment of moderate or severe ulcerative colitis (for… · AbbVie GK · Sep 27, 2021
HumiraDrugs with a new indication and a new dosage for the treatment of pyoderma gangrenosum. · AbbVie GK · Nov 27, 2020
HumiraDrugs with a new dosage indicated for the treatment of hidradenitis suppurativa. · AbbVie GK · May 29, 2020
HumiraDrugs with a new additional indication and a new dosage for the treatment of hidradenitis suppurativa. · AbbVie GK · Feb 21, 2019
HumiraDrugs with a new additional indication and a new dosage indicated for the treatment of pustular psoriasis in patients who have not responded sufficiently to… · AbbVie GK · Mar 23, 2018
HumiraDrugs with a new additional indication and a new dosage for the treatment of non-infectious intermediate, posterior, and panuveitis in patients who have not… · AbbVie GK · Sep 28, 2016 · Review report
HumiraA drug with a new dosage indicated for the treatment of Crohn's disease. · AbbVie GK · Jun 20, 2016
Approvals in Canada (Health Canada)
First approved in Canada 207 months before the US. New drug submissions since 1994, matched by ingredient; see all Canadian approvals
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Mechanisms, targets, withdrawals and boxed warnings are from ChEMBL (EMBL-EBI, CC BY-SA 3.0), matched by ingredient name. How trials ended is TrialPanorama's classification of ClinicalTrials.gov records (Wang et al. 2025, Apache-2.0), matched by the intervention name each trial registered.Drugs@FDA